Human cathepsin L (hCatL) serves as a lysosomal cysteine protease. It significantly facilitates endosomal entry for the SARS-CoV-2 virus. Therefore, researchers identify it as a critical therapeutic target for COVID-19 treatment. Recently, a team developed new cathepsin L inhibitors featuring tripeptidomimetic structures. These compounds utilize electrophilic α,β-unsaturated ethyl ester or sulfone warheads. Consequently, these inactivators demonstrate remarkable potency against viral infection in cellular models.

Potency and Mechanism of Cathepsin L Inhibitors

The study evaluated several irreversible inactivators for their biochemical and antiviral activity. These compounds showed IC₅₀ values between 0.4 and 35 nM. Specifically, inhibitors 16 and 17 emerged as the most potent candidates in the series. In Vero E6 cells, they achieved EC₅₀ values from 120 to 310 nM. Furthermore, tests in A549/ACE2 cells showed even higher efficacy. These inhibitors reached EC₅₀ levels between 78 and 120 nM. Thus, the molecules effectively block the endosomal entry pathway. This process prevents the virus from replicating within human cells.

Future Potential for COVID-19 Therapies

Host-targeted therapies offer several advantages over traditional antivirals. For example, host enzymes like cathepsin L do not mutate as quickly as viral proteins. Consequently, these inhibitors might maintain efficacy against multiple SARS-CoV-2 variants. Moreover, the study demonstrates that these peptidomimetics possess high metabolic stability. Scientists are now investigating their pharmacokinetic profiles in more detail. In addition, these findings pave the way for broad-spectrum antiviral development. Such drugs could protect against future emerging coronaviruses.

Frequently Asked Questions

What makes cathepsin L a good target for COVID-19 drugs?

Cathepsin L is an essential enzyme that the virus uses to enter host cells. Because it is a human protein, it is less likely to undergo mutations that cause drug resistance. This makes it a stable target for long-term therapy.

How effective are these new peptidomimetic inhibitors?

These inhibitors show sub-nanomolar potency in enzyme assays. In cell cultures, they successfully block SARS-CoV-2 infection at very low concentrations. This high efficiency suggests they could be potent therapeutic agents.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Kumar V et al. Peptidomimetic α,β-Unsaturated Ethyl Esters Are Irreversible Inactivators of Human Cathepsin L and Are Potent Inhibitors of SARS-CoV-2 in Cellular Models of COVID-19. J Med Chem. 2026 Apr 21. doi: 10.1021/acs.jmedchem.5c03172. PMID: 42014929.


2. Smieszek SP et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6(1):134.


3. Zhao M et al. Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity. J Med Chem. 2021;64(11):7367-7382.